Physician profile
Mitchell R Smith
NPI 1013939206
$40,556.38
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $12K · 2021: $4,930 · 2022: $1,950 · 2023: $13.11 · 2024: $26.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eusa Pharma (US) LLC | $10,318.88 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $8,547.89 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $6,984.25 | 2019 | |
| Kite Pharma, INC. | $5,390.00 | 2020 | |
| Aurobindo Pharma USA, INC. | $4,534.02 | 2019 | |
| Acrotech Biopharma INC. | $1,950.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $1,500.00 | 2020 | |
| Secura Bio, INC. | $804.95 | 2021 | |
| Seagen INC. | $203.85 | 2019 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Verastem, INC. | $94.42 | 2019 | |
| Mckesson Specialty Care Distribution, LLC | $32.73 | 2020 | |
| Janssen Biotech, INC. | $31.35 | 2019 | |
| Genentech USA, INC. | $26.88 | 2019-2023 | Polivy, Lunsumio, Columvi |
| Abbott Laboratories | $26.13 | 2024 | Proclaim |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.